Top 5 Papers
#1
Source: Journal of Clinical Oncology | Authors: Peng, Wang, Zhang, et al. | Published: September 24, 2026
Score: 13/20 — Base: JCO (8) + Phase III RCT (+3) + survival benefit in both OS and PFS (+2) = 13. No new-standard-of-care bonus applied: the comparator was chemotherapy alone, not the PD-1 inhibitor plus chemotherapy regimen that is now approved first-line standard of care, so the trial cannot establish a new standard against current practice.
RELIGHT randomized 731 previously untreated patients with unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma 1:1 to retlirafusp alfa — an anti-PD-L1/TGF-β bispecific antibody — or placebo every 3 weeks, on top of capecitabine and oxaliplatin. In the PD-L1 CPS≥5 population median OS was 16.8 vs 10.4 months (stratified HR 0.53, 95% CI 0.40–0.68, one-sided p<0.0001), and in the intention-to-treat set 15.8 vs 11.2 months (stratified HR 0.66, 95% CI 0.53–0.81, one-sided p<0.0001). PFS moved the same way: 7.6 vs 5.5 months in CPS≥5 (HR 0.52, 95% CI 0.42–0.66) and 7.0 vs 5.5 months in ITT (HR 0.57, 95% CI 0.48–0.69). Grade ≥3 treatment-related adverse events were essentially flat at 62.6% (228/364) vs 59.0% (216/366). The asterisk is the control arm, and the authors say so themselves: the protocol was finalized before PD-1 inhibitor plus chemotherapy became approved standard of care in China, so this is a bispecific beating chemotherapy alone — not beating the regimen a patient would actually be offered today.
Post angle: A 47% reduction in death risk in PD-L1 CPS≥5 first-line gastric cancer is the kind of number that changes practice — except the control arm is chemotherapy alone, a regimen we stopped using. Dual PD-L1/TGF-β blockade deserves a head-to-head against PD-1 plus chemo. #GIOnc #GastricCancer #PrecisionMedicine
#2
Source: Nature Medicine | Authors: Shitara, Wainberg, Tabernero, et al. | Published: September 24, 2026
Score: 12/20 — Base: Nature Medicine (9) + randomized Phase II (+2) + biomarker-guided/precision, via fresh-biopsy HER2 reconfirmation and CD47 expression analysis (+1) = 12. No survival-benefit bonus: the primary endpoint was ORR, and the response rate did not meet the prespecified statistical criterion against the historical benchmark.
The phase 2 portion of ASPEN-06 randomized 127 patients with pretreated, HER2-overexpressing advanced gastric/gastroesophageal junction cancer to evorpacept — which blocks the CD47–SIRPα interaction to enhance antibody-dependent cellular phagocytosis — added to trastuzumab, ramucirumab and paclitaxel (TRP), or to TRP alone. Investigator-assessed ORR was 40.3% vs 26.6% in the ITT population and 54.8% vs 23.1% in the subgroup whose HER2 overexpression was confirmed on a fresh post-trastuzumab biopsy. Both ORR differences (13.7% and 31.7%) cleared the prespecified margins versus TRP, meeting one of the two primary objectives — but measured against the historical 30% ramucirumab/paclitaxel benchmark, neither crossed the one-sided α=0.025 threshold (p=0.0949 in ITT; p=0.030 in the fresh-biopsy subgroup). Hematologic toxicities were more common with evorpacept, while overall safety was similar. The signal worth following is the fresh-biopsy subgroup: re-confirming HER2 after trastuzumab exposure more than doubled the response gap, which is a statement about patient selection as much as about CD47.
Post angle: ASPEN-06 is a lesson in how you define the denominator. Evorpacept nearly doubled ORR in patients whose HER2 was still there on a fresh biopsy — and the trial still missed its statistical bar against a historical benchmark. Re-biopsy after trastuzumab is the takeaway. #GIOnc #HER2 #GastricCancer
#3
Source: Gastroenterology | Authors: Devarbhavi, et al. | Published: September 25, 2026
Score: 8/20 — Base: Gastroenterology (7) + population-level real-world burden data (+1) = 8. No study-type bonus for the review format itself; the added point reflects the epidemiologic burden estimates rather than the narrative synthesis.
Gastroenterology's 2026 update puts chronic liver disease at more than 1.5 billion people worldwide, with cirrhosis now the 12th leading cause of death globally and cirrhosis together with primary liver cancer accounting for nearly 2.4 million deaths annually. The burden is driven by alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease (MASLD), and chronic hepatitis B and C, with demographic change, rising obesity and increasing alcohol consumption expected to push ALD and MASLD higher while vaccination and antiviral access continue to reshape the viral hepatitis curve. The shift that matters most for oncologists: Africa now bears the highest age-standardized mortality rates from both cirrhosis and liver cancer, driven largely by viral hepatitis and aflatoxin exposure. Low- and middle-income countries absorb a disproportionate share of the deaths while having the least access to advanced therapy, and cirrhosis itself carries elevated risk of progression to decompensation, acute-on-chronic liver failure and hepatocellular carcinoma.
Post angle: HCC is downstream of a prevention failure, and the 2026 burden update makes the geography explicit: Africa now has the world's highest age-standardized mortality from both cirrhosis and liver cancer. Aflatoxin and viral hepatitis, not drug access, are the levers. #GIOnc #HCC #MASLD #GlobalHealth
#4
Source: JAMA Oncology | Authors: Weil, et al. | Published: September 24, 2026
Score: 8/20 — Base: JAMA Oncology (7) + synthesis of retrospective/real-world data across 24 studies (+1) = 8. Scored as a narrative review, not a meta-analysis: no pooled effect estimate is reported, so the +2 meta-analysis bonus does not apply.
This JAMA Oncology narrative review assembled 24 retrospective studies comprising 2,705 patients with ovarian metastases from colorectal cancer to test a long-standing clinical suspicion — that the ovary behaves as a chemotherapy-resistant sanctuary site. The evidence supports it. Ovarian deposits showed lower objective chemotherapy response rates than extraovarian metastases, substantially lower mean shrinkage, and frequently exhibited discordant growth during treatment while other sites responded. The most favorable survival outcomes were in patients who underwent complete surgical resection of ovarian metastases with microscopically negative margins. The practical conclusion is that systemic therapy alone should not be regarded as adequate treatment for ovarian metastatic disease: chemotherapy's role becomes reduction of overall tumor burden to improve candidacy for resection, with management aimed at clearing all macroscopic disease and resecting the primary tumor within a comprehensive disease-control strategy.
Post angle: If a colorectal cancer patient's ovarian metastasis is growing while everything else shrinks, that is not treatment failure — it is pharmacology. 2,705 patients across 24 studies support the ovary as a sanctuary site. Plan for resection, not more lines of chemo. #GIOnc #CRC #ColorectalCancer
#5
Source: Gut | Authors: Barman, et al. (PeriOperative Quality Initiative) | Published: September 25, 2026
Score: 7/20 — Base: Gut (7) = 7. No study-type or impact bonus: a society-endorsed Delphi consensus statement is not a trial and reports no efficacy endpoint, so it is scored on journal prestige alone rather than credited with a survival or standard-of-care bonus it did not measure.
Symptoms after upper gastrointestinal cancer surgery are common, frequently overlapping, and substantially damaging to quality of life — yet there has been little standardisation in how the responsible postoperative conditions are defined, investigated or managed. EUROSTAR is a society-endorsed, European-wide answer: a multidisciplinary panel of experts from 10 European countries, selected for expertise in UGI cancer survivorship, ran a modified Delphi process developed by the PeriOperative Quality Initiative (POQI), with independent POQI oversight and statements graded using modified GRADE against a comprehensive literature review. The output is 8 statements and 13 recommendations covering symptom monitoring and service provision after major UGI cancer surgery, plus diagnostic criteria, investigation pathways and management recommendations for the specific postoperative conditions that generate these symptoms. For anyone running a survivorship clinic, this supplies the missing shared vocabulary — it converts "my patient cannot eat" into a named condition with a defined workup.
Post angle: We have consensus documents for every line of therapy in oesophago-gastric cancer and almost nothing for what happens to patients after resection. EUROSTAR gives survivorship 8 statements, 13 recommendations, and — finally — diagnostic criteria. #GIOnc #EsophagealCancer #GastricCancer #Survivorship
Additional Papers of Interest
-
Gut — Multidisciplinary consensus reaching 9 statements each for neoadjuvant/perioperative and combination locoregional-plus-systemic HCC trials, recommending enrolment of the highest-recurrence-risk patients and 2-year event-free survival by restricted mean survival time as the primary endpoint
-
Nature Communications — DNA-binding-domain TP53 mutations drive RBM28 overexpression, which over-splices transposon elements and blocks double-stranded RNA formation and type I interferon signalling; shown across human multi-stage esophageal cancer development, with restored p53 conformation or splicing inhibition resensitising tumours to immune checkpoint blockade
-
Endoscopy — European Society of Gastrointestinal Endoscopy sets proficiency in both endoscopic resection and ablation as mandatory for competence in early Barrett neoplasia, a minimum of 10 supervised model cases before human training, and an annual caseload of at least 10 new resection and 10 new ablation cases per endoscopist to maintain competence
-
JAMA Oncology — Across 589,766 adults in three prospective cohorts and 70,300 cancers, 11 modifiable factors (including cholelithiasis and chronic liver disease) accounted for 84.44% of the sex gap in China, led by smoking (AP 51.75%) and heavy alcohol use (AP 15.10%), versus 26.21% in UK Biobank, led by obesity (AP 7.68%)
-
ESMO Gastrointestinal Oncology — A 26-expert European modified Delphi panel agreed that immunotherapy is an efficacious standard of care in dMMR/MSI-high locally advanced rectal cancer, with high complete-response rates enabling organ preservation, and flagged reflex mismatch repair/MSI testing, reimbursement variability and the absence of long-term data and response biomarkers as the outstanding gaps
-
ESMO Gastrointestinal Oncology — In a US claims analysis, the 4.4% of patients under 50 had longer time to diagnosis (expβ 1.13, 95% CI 1.07–1.20) and higher odds of a ≥30-day diagnostic delay (OR 1.24, 95% CI 1.12–1.36), were slightly more likely to receive cancer-directed therapy (OR 1.12, 95% CI 1.01–1.25), and showed treatment-receipt disparities among racial minorities and publicly insured patients
Back to all digests